Skip to main content

Advertisement

Log in

Cholinesterase inhibitors and memantine have a role in the treatment of Alzheimer's disease

  • Viewpoint
  • Published:

From Nature Clinical Practice Neurology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kaduszkiewicz H et al. (2005) Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ 331: 321–327

    Article  CAS  Google Scholar 

  2. McShane R and Schneider L (2005) Meta-analysis of memantine: summary and commentary on the Cochrane Collaboration's systematic review. Alzheimer's and Dementia 1: 67–71

    Article  CAS  Google Scholar 

  3. Doody RS et al. (2001) Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1154–1166

    Article  CAS  Google Scholar 

  4. American Psychiatric Association: Treatment Guideline: Alzheimer's disease and other dementias of late life. Am J Psychiatry, in press

  5. Peterson R et al. (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 1–10

    Article  Google Scholar 

  6. Trinh N et al. (2003) Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 289: 210–216

    Article  CAS  Google Scholar 

  7. Rabins P et al. (1982) The impact of dementia on the family. JAMA 248: 333–335

    Article  CAS  Google Scholar 

  8. Lyketsos CG et al. (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. JAMA 288: 1475–1483

    Article  Google Scholar 

  9. Winblad B et al. (2006) Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 367: 1057–1065.

    Article  CAS  Google Scholar 

  10. Rabins P et al. (2006) Practical Dementia Care. Oxford and New York: Oxford University Press

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter V Rabins.

Ethics declarations

Competing interests

Peter Rabins has received speaking honoraria from AstraZeneca, Eli Lilly, Forest Laboratories, Janssen Pharmaceutica and Pfizer.

Constantine Lyketsos has received research funding and educational fees from Abbott Laboratories, AstraZeneca, Bristol–Myers Squibb, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutica and Pfizer, and consulting or advisory board fees from Eisai, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica and Novartis, and lecture fees from Forest Laboratories, Lundbeck and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rabins, P., Lyketsos, C. Cholinesterase inhibitors and memantine have a role in the treatment of Alzheimer's disease. Nat Rev Neurol 2, 578–579 (2006). https://doi.org/10.1038/ncpneuro0269

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0269

  • Springer Nature Limited

This article is cited by

Navigation